(S (S (NP (NNP Drug)) (VP (VBG repositioning))) (, ,) (NP (DT that)) (VP (VBZ is) (VP (VBG finding) (NP (JJ new) (NNS uses)) (PP (IN for) (NP (VBG existing) (NNS drugs))) (S (VP (TO to) (VP (VB treat) (NP (JJR more) (NNS patients))))))) (. .))
(S (NP (JJ Cumulative) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (JJ mature) (NNS miRNAs)) (CONJP (RB as) (RB well) (IN as)) (NP (PRP$ their) (NNS precursors))) (VP (MD can) (VP (VB be) (VP (VBN targeted) (PP (IN by) (NP (JJ small) (JJ molecular) (NNS drugs))))))))) (. .))
(S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (JJ human) (NNS diseases)) (VP (VBP result) (PP (IN from) (NP (NP (DT the) (JJ disordered) (NN interplay)) (PP (IN of) (NP (NML (NN tissue) (HYPH -) (CC and) (NN cell)) (ADJP (NN lineage) (HYPH -) (JJ specific)) (NNS processes)))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (JJ few) (JJ computational) (NNS researches)) (VP (VBP predict) (NP (NP (NML (NN drug) (HYPH -) (NN disease)) (JJ potential) (NNS relationships)) (PP (VBN based) (PP (IN on) (NP (NP (NN miRNA) (NNS data)) (CC and) (NP (NN tissue) (NN specificity))))))) (. .))
(S (ADVP (RB Therefore)) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (NN miRNA) (NNS data)) (CC and) (NP (NP (DT the) (NN tissue) (NN specificity)) (PP (IN of) (NP (NNS diseases))))))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ new) (NN method)) (VP (VBN named) (PP (IN as) (NP (NN miTS))) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (JJ potential) (NNS treatments)) (PP (IN for) (NP (NNS diseases)))))))))) (. .))
(S (S (ADVP (RB Firstly)) (, ,) (PP (VBN based) (PP (IN on) (NP (NNS miRNAs) (NNS data)))) (, ,) (NP (NP (NN target) (NNS genes)) (CC and) (NP (NP (NN information)) (PP (IN of) (NP (NNP FDA))))) (VP (VBD approved) (NP (NNS drugs)))) (, ,) (NP (PRP we)) (VP (VBP evaluate) (NP (NP (DT the) (NNS relationships)) (PP (IN between) (NP (NNS miRNAs) (CC and) (NNS drugs)))) (PP (IN in) (NP (DT the) (ADJP (NN tissue) (HYPH -) (JJ specific)) (NNP PPI) (NN network)))) (. .))
(S (S (ADVP (RB Then)) (, ,) (NP (PRP we)) (VP (VBP construct) (NP (DT a) (JJ tripartite) (NN network)))) (: :) (S (NP (NN drug) (HYPH -) (NN miRNA) (HYPH -) (NN disease)) (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBP obtain) (NP (DT the) (JJ potential) (NML (NN drug) (HYPH -) (NN disease)) (NNS associations)) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ tripartite) (NN network)))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (S (NP (PRP we)) (VP (VBP take) (NP (NN breast) (NN cancer)) (PP (IN as) (NP (NN case) (NN study))))) (CC and) (S (S (VP (VB focus) (PP (IN on) (NP (DT the) (NML (JJ top) (HYPH -) (CD 30)))))) (VP (VBD predicted) (NP (NNS drugs)))) (. .))
(S (S (NP (NP (CD 25)) (PP (IN of) (NP (PRP them))) (PRN (-LRB- -LRB-) (NP (CD 83.3) (NN %)) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN found) (S (VP (VBG having) (VP (VBN known) (NP (NNS connections)) (PP (IN with) (NP (NP (NN breast) (NN cancer)) (PP (IN in) (NP (NNP CTD) (NN benchmark))))))))))) (CC and) (S (NP (DT the) (JJ other) (CD 5) (NNS drugs)) (VP (VBP are) (NP (NP (JJ potential) (NNS drugs)) (PP (IN for) (NP (NN breast) (NN cancer)))))) (. .))
(S (NP (PRP We)) (ADVP (RB further)) (VP (VB evaluate) (NP (NP (DT the) (CD 5) (ADJP (RB newly) (VBN predicted)) (NNS drugs)) (PP (IN from) (NP (JJ clinical) (NNS records))) (, ,) (NP (NN literature) (NN mining)) (, ,) (NP (NML (NML (NN KEGG) (NNS pathways)) (NN enrichment)) (NN analysis)) (CC and) (NP (NP (VBG overlapping) (NNS genes)) (PP (IN between) (NP (JJ enriched) (NNS pathways)))))) (. .))
(S (PP (IN For) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (CD 5) (JJ new) (NNS drugs))))) (, ,) (ADVP (RB strongly)) (VP (VBD supported) (SBAR (S (NP (NNS evidences)) (VP (MD can) (VP (VB be) (VP (VBN found) (PP (IN in) (NP (QP (CD three) (CC or) (JJR more)) (NNS aspects))))))))) (. .))
(S (PP (IN In) (ADJP (JJ particular))) (, ,) (S (NP (NNP Regorafenib)) (VP (VBZ has) (NP (NP (CD 15) (VBG overlapping) (NN KEGG) (NNS pathways)) (PP (IN with) (NP (NN breast) (NN cancer)))))) (CC and) (S (NP (PRP$ their) (NN p) (HYPH -) (NNS values)) (VP (VBP are) (ADJP (DT all) (RB very) (JJ small)))) (. .))
(S (PP (IN In) (NP (NP (NN addition)) (, ,) (SBAR (IN whether) (FRAG (PP (IN in) (NP (NP (DT the) (NN literature) (NN curation)) (CC or) (NP (JJ clinical) (NN validation)))))))) (, ,) (NP (NNP Regorafenib)) (VP (VBZ has) (NP (NP (DT a) (JJ strong) (NN correlation)) (PP (IN with) (NP (NN breast) (NN cancer))))) (. .))
(S (NP (PDT All) (DT the) (NNS facts)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Regorafenib)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (ADJP (RB truly) (JJ effective)) (NN drug)) (, ,) (ADJP (JJ worthy) (PP (IN of) (NP (PRP$ our) (JJ further) (NN study))))))))))))) (. .))
(S (NP (PRP It)) (ADVP (RB further)) (VP (VBZ follows) (SBAR (IN that) (S (NP (PRP$ our) (NN method) (NN miTS)) (VP (VBZ is) (ADJP (JJ effective) (CC and) (JJ practical) (PP (IN for) (S (VP (VBG predicting) (NP (JJ new) (NN drug) (NNS indications)))))))))) (. .))
